Investment Thesis
Arcellx is a pre-commercial biotech company facing severe financial distress with massive operating losses, negative free cash flow of -$212.6M, and revenue declining 79.4% YoY, indicating potential clinical trial setbacks or delayed commercialization. The company is burning cash at an unsustainable rate with only $80.3M in cash reserves against $210.3M in annual operating cash burn, creating an imminent liquidity crisis within months. Without immediate major value-creating catalysts or significant capital raises, the company's financial runway appears critically short.
ACLX Strengths
- Adequate current ratio of 4.44x suggests near-term liquidity for operational needs
- No long-term debt obligation provides flexibility and avoids near-term refinancing risk
- Substantial stockholders equity of $402.4M represents remaining asset base
ACLX Risks
- Catastrophic revenue decline of 79.4% YoY with only $22.3M in current revenue indicates failed commercialization or trial failure
- Annual operating cash burn of $210.3M against $80.3M cash reserves means runway of less than 5 months at current burn rate
- Operating margin of -1135.6% and net margin of -1027.3% are unsustainable; company is pre-revenue/pre-profitability with massive R&D costs
- Negative free cash flow of -$212.6M demonstrates the company cannot sustain operations without external funding
- 14 Form 4 insider filings in 90 days may signal insider concerns or significant management transitions
Key Metrics to Watch
- Monthly cash burn rate and actual runway remaining until capital depletion
- Clinical trial results and regulatory pathway milestones for pipeline programs
- Revenue trends and commercial traction for any approved or approved-pending therapies
- Capital raise announcements or financing activities to extend runway
- Changes in insider ownership patterns and management retention
ACLX Financial Metrics
ACLX Profitability Ratios
ACLX Balance Sheet & Liquidity
ACLX 5-Year Financial Trend
5-Year Trend Summary: Arcellx, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.47 indicates the company is currently unprofitable.
ACLX Growth Metrics (YoY)
ACLX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.9M | -$7.2M | $-0.48 |
| Q2 2025 | $7.6M | -$7.2M | $-0.51 |
| Q1 2025 | $8.1M | -$7.2M | $-0.14 |
| Q3 2024 | $15.0M | -$7.2M | $-0.48 |
| Q2 2024 | $14.3M | -$7.2M | $-0.50 |
| Q1 2024 | $17.9M | -$7.2M | $-0.14 |
| Q3 2023 | $15.0M | -$23.9M | $-0.81 |
| Q2 2023 | $14.3M | -$23.9M | $-0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ACLX Capital Allocation
ACLX SEC Filings
Access official SEC EDGAR filings for Arcellx, Inc. (CIK: 0001786205)